BiotechTube

Ifinatamab deruxtecan + Atezolizumab + Carboplatin

Phase 1/2Recruiting
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Extensive Stage-small Cell Lung Cancer

Conditions

Extensive Stage-small Cell Lung Cancer

Trial Timeline

Jul 22, 2024 → Dec 30, 2026

NCT ID
NCT06362252

About Ifinatamab deruxtecan + Atezolizumab + Carboplatin

Ifinatamab deruxtecan + Atezolizumab + Carboplatin is a phase 1/2 stage product being developed by Daiichi Sankyo for Extensive Stage-small Cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06362252. Target conditions include Extensive Stage-small Cell Lung Cancer.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT06362252Phase 1/2Recruiting

Competing Products

20 competing products in Extensive Stage-small Cell Lung Cancer

See all competitors
ProductCompanyStageHype Score
ALPS12 + obinutuzumabChugai PharmaceuticalPhase 1
33
Ifinatamab Deruxtecan (I-DXd)Daiichi SankyoPhase 2
52
Gocatamig + I-DXd + Atezolizumab + Carboplatin + Etoposide + Rescue MedicationsDaiichi SankyoPhase 1/2
41
Valemetostat + AtezolizumabDaiichi SankyoPhase 1
33
LY2510924 + Carboplatin + EtoposideEli LillyPhase 2
52
SHR-1316 + Carboplatin + Etoposide + PlaceboJiangsu Hengrui MedicinePhase 3
77
Epirubicin plus SHR1210Jiangsu Hengrui MedicinePhase 2
52
Durvalumab plus chemotherapyAstraZenecaPhase 3
77
Durvalumab + Tremelimumab + Olaparib Pill + TremelimumabAstraZenecaPhase 1
33
Neoantigen DNA vaccine + DurvalumabAstraZenecaPhase 2
52
Etoposide with Carboplatin or Cisplatin + DurvalumabAstraZenecaPhase 2
52
Durvalumab 50 MG/1 ML Intravenous Solution + Etoposide Injection + Cisplatin + CarboplatinAstraZenecaPhase 1
33
Durvalumab and Tremelimumab + AZD1775 and carboplatin (CBPT) + AZD6738 and olaparibAstraZenecaPhase 2
52
Durvalumab + Cisplatin + Etoposide + CarboplatinAstraZenecaPhase 3
77
Durvalumab + Cisplatin + Carboplatin + EtoposideAstraZenecaPhase 3
77
Cisplatin + Carboplatin + Etoposide + Durvalumab + CeralasertibAstraZenecaPhase 2
52
Carboplatin + Cisplatin + Durvalumab + EtoposideAstraZenecaPhase 2
52
Carboplatin + Durvalumab + Etoposide + OlaparibAstraZenecaPhase 1/2
41
Durvalumab + Tremelimumab + Carboplatin + Cisplatin + EtoposideAstraZenecaPhase 3
77
Bomedemstat + AtezolizumabMerckPhase 1/2
41

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved
85
OAC aloneApproved
85
olmesartan medoxomil + Placebo + losartan potassiumApproved
85
Prasugrel + ClopidogrelApproved
85
Diet+pravastatinApproved
85